US2017253646A1PendingUtilityA1

Functional Peptide Analogs of PEDF

Assignee: PENN STATE RES FOUNDPriority: Sep 13, 2013Filed: Apr 3, 2017Published: Sep 7, 2017

Est. expirySep 13, 2033(~7.1 yrs left)· nominal 20-yr term from priority

Inventors:Joyce Tombran-Tink Colin J. Barnstable

A61P 9/10A61K 38/55C07K 2317/76A61K 38/00A61K 9/0048A61P 27/02C07K 16/38G01N 33/5023G01N 33/5008C07K 7/08C07K 14/8121

PatentIndex Score

Cited by

References

Claims

Abstract

The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.

Claims

exact text as granted — not AI-modified

1 - 36 . (canceled) 
     
     
         37 . A composition comprising at least one peptide analog of pigment epithelium derived factor (PEDF), wherein the at least one peptide analog comprises at least one selected from the group consisting of SpxA1 (SEQ ID NO: 44), 81-1 (SEQ ID NO: 1), 81-2 (SEQ ID NO: 2), 81-6 (SEQ ID NO: 6), 81-7 (SEQ ID NO: 7), 81-8 (SEQ ID NO: 8), 81-9 (SEQ ID NO: 9), 81-11 (SEQ ID NO: 11), 81-12 (SEQ ID NO: 12), 81-13 (SEQ ID NO: 13), 81-14 (SEQ ID NO: 14), 81-15 (SEQ ID NO: 15), 81-16 (SEQ ID NO: 16), 81-17 (SEQ ID NO: 17), 81-18 (SEQ ID NO: 18), 81-19 (SEQ ID NO: 19), and 81-20 (SEQ ID NO: 20). 
     
     
         38 . The composition of  claim 37 , wherein the composition further comprises a pharmaceutical carrier. 
     
     
         39 . The composition of  claim 37 , wherein the at least one peptide analog comprises at least one peptide analog selected from the group consisting of SpxA1 (SEQ ID NO: 44), 81-2 (SEQ ID NO: 2), 81-12 (SEQ ID NO: 12), 81-13 (SEQ ID NO: 13), and 81-20 (SEQ ID NO: 20). 
     
     
         40 . The composition of  claim 37 , wherein the composition is configured for delivery to the eye of a subject. 
     
     
         41 . The composition of  claim 37 , wherein the composition is formulated as an eye drop, a gel, a foam or an injectate. 
     
     
         42 . A method for reducing inflammation in a subject in need thereof, the method comprising administering to a subject a therapeutically effective amount of a composition comprising at least one peptide analog of PEDF. 
     
     
         43 . The method of  claim 42 , wherein the at least one peptide analog comprises at least one selected from the group consisting of SpxA1 (SEQ ID NO: 44), 81-1 (SEQ ID NO: 1), 81-2 (SEQ ID NO: 2), 81-6 (SEQ ID NO: 6), 81-7 (SEQ ID NO: 7), 81-8 (SEQ ID NO: 8), 81-9 (SEQ ID NO: 9), 81-11 (SEQ ID NO: 11), 81-12 (SEQ ID NO: 12), 81-13 (SEQ ID NO: 13), 81-14 (SEQ ID NO: 14), 81-15 (SEQ ID NO: 15), 81-16 (SEQ ID NO: 16), 81-17 (SEQ ID NO: 17), 81-18 (SEQ ID NO: 18), 81-19 (SEQ ID NO: 19), and 81-20 (SEQ ID NO: 20). 
     
     
         44 . The method of  claim 42 , wherein the composition is formulated as an eye drop, a gel, a foam or an injectate. 
     
     
         45 . The method of  claim 42 , wherein the disease or disorder is associated with angiogenesis. 
     
     
         46 . The method of  claim 42 , wherein the disease or disorder is selected from the group consisting of diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinitis pigmentosis, glaucoma, uveitis, corneal inflammation, diabetes, a neurodegenerative disease, nerve injury, sepsis, acute respiratory distress syndrome, nephrotic syndrome, diabetic neuropathy, preproliferative diabetic retinopathy, proliferative diabetic retinopathy, cancer, and cystic fibrosis. 
     
     
         47 . The method of  claim 42 , wherein the subject is a mammal. 
     
     
         48 . The method of  claim 42 , wherein the mammal is a human. 
     
     
         49 . A method of reducing the level of VEGF in a subject, the method comprising administering to a subject a composition comprising at least one peptide analog of PEDF. 
     
     
         50 . The method of  claim 49 , wherein the at least one peptide analog comprises at least one selected from the group consisting of SpxA1 (SEQ ID NO: 44), 81-1 (SEQ ID NO: 1), 81-2 (SEQ ID NO: 2), 81-6 (SEQ ID NO: 6), 81-7 (SEQ ID NO: 7), 81-8 (SEQ ID NO: 8), 81-9 (SEQ ID NO: 9), 81-11 (SEQ ID NO: 11), 81-12 (SEQ ID NO: 12), 81-13 (SEQ ID NO: 13), 81-14 (SEQ ID NO: 14), 81-15 (SEQ ID NO: 15), 81-16 (SEQ ID NO: 16), 81-17 (SEQ ID NO: 17), 81-18 (SEQ ID NO: 18), 81-19 (SEQ ID NO: 19), and 81-20 (SEQ ID NO: 20). 
     
     
         51 . A method of culturing a stem cell comprising contacting the stem cell with at least one peptide analog of PEDF, wherein the at least peptide analog comprises at least one selected from the group consisting of SpxA1 (SEQ ID NO: 44), 81-1 (SEQ ID NO: 1), 81-2 (SEQ ID NO: 2), 81-6 (SEQ ID NO: 6), 81-7 (SEQ ID NO: 7), 81-8 (SEQ ID NO: 8), 81-9 (SEQ ID NO: 9), 81-11 (SEQ ID NO: 11), 81-12 (SEQ ID NO: 12), 81-13 (SEQ ID NO: 13), 81-14 (SEQ ID NO: 14), 81-15 (SEQ ID NO: 15), 81-16 (SEQ ID NO: 16), 81-17 (SEQ ID NO: 17), 81-18 (SEQ ID NO: 18), 81-19 (SEQ ID NO: 19), and 81-20 (SEQ ID NO: 20). 
     
     
         52 . The method of  claim 51 , wherein the method comprises contacting the cell with a liquid medium comprising the at least one peptide analog. 
     
     
         53 . The method of  claim 52 , wherein the composition is formulated as an implant wherein the implant releases the peptide analog.

Join the waitlist — get patent alerts

Track US2017253646A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.